Liminatus Pharma Completes Merger with IRIS Acquisition

Liminatus Pharma ( (LIMN) ) has provided an update.

Liminatus Pharma completed a business combination with IRIS Acquisition Corp. in May 2025, with its shares now trading on the Nasdaq Global Market under the ticker symbol ‘LIMN.’ The company is advancing its proprietary CD47 blockade, IBA101, which aims to improve the safety profile of cancer treatments by overcoming issues like anemia and thrombocytopenia associated with first-generation CD47 antibodies. Liminatus plans to leverage partnerships with major pharmaceutical companies and aims to expand its market potential by combining CD47 blockade with PD-1/PD-L1 inhibitors, potentially enhancing antitumor activity by at least 10%.

More about Liminatus Pharma

Liminatus Pharma is an immunotherapy company focused on developing a CD47-blocking antibody for treating solid tumors. The company is preparing for an FDA Phase I clinical trial and plans to expand its pipeline by in-licensing CAR-T cell therapeutics and companion diagnostic technologies.

Average Trading Volume: 301,370

Technical Sentiment Signal: Strong Buy

Current Market Cap: $375.4M

For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.